Clinical and Economic Outcomes of Dronedarone Versus Amiodarone Among Patients With Atrial Fibrillation
Open Access
- 6 January 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e042178
Abstract
Background: This retrospective observational study compared adverse events (AEs) and health care resource use among patients with atrial fibrillation treated with dronedarone versus amiodarone. Methods: Adults with atrial fibrillation who initiated dronedarone or amiodarone between January 1, 2010 and September 30, 2021 were propensity score matched in Optum’s deidentified Clinformatics Data Mart Database. Outcomes included AEs (described in the dronedarone/amiodarone Food and Drug Administration labels and reported in the Food and Drug Administration AE Reporting System) and all‐cause and cardiovascular‐related health care resource use. Generalized linear models with Poisson distribution were used to compare the risk of AEs between the 2 cohorts. After matching, 12 210 dronedarone‐treated patients were paired 1:1 with amiodarone‐treated patients. For each AE, patients who experienced the AE during baseline were excluded. Results: During follow‐up, lower event rates of AEs were observed with dronedarone versus amiodarone; the rate ratio for any cardiac and vascular AE was 0.71 (95% CI, 0.69–0.72), any respiratory AE was 0.65 (95% CI, 0.63–0.66), and any gastrointestinal/hepatobiliary AE was 0.81 (95% CI, 0.79–0.84). Compared with amiodarone‐treated patients, dronedarone‐treated patients experienced lower event rates of all‐cause hospitalization (0.69 [95% CI, 0.67–0.71]) and all‐cause outpatient visits (0.87 [95% CI, 0.87–0.87]). Although the incidence of cardiovascular‐related hospitalization was higher with dronedarone versus amiodarone, event rates were not statistically different. Cardiovascular‐related outpatient visits were significantly reduced with dronedarone versus amiodarone with an event rate of 0.95 (95% CI, 0.94–0.96). Conclusions: In this study, lower event/incidence rates of AEs and health care resource use were observed in patients with atrial fibrillation treated with dronedarone versus amiodarone.Keywords
This publication has 30 references indexed in Scilit:
- Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta‐analysisClinical Cardiology, 2023
- Amiodarone vs Dronedarone for Atrial Fibrillation: A Retrospective Cohort StudyCJC Open, 2022
- Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmicsPharmacoepidemiology and Drug Safety, 2021
- Outcomes Associated with Dronedarone Use in Patients with Atrial FibrillationThe American Journal of Cardiology, 2020
- Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in GermanyInternational Journal of Cardiology, 2019
- Association of frailty with short-term outcomes, organ support and resource use in critically ill patientsIntensive Care Medicine, 2018
- Efficacy and Safety of Dronedarone in Patients Previously Treated With Other Antiarrhythmic AgentsClinical Cardiology, 2014
- Safety of Dronedarone in Routine Clinical CareJACC, 2014
- Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or FlutterNew England Journal of Medicine, 2007
- Prevalence of Diagnosed Atrial Fibrillation in AdultsJAMA, 2001